throbber
Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 1 of 26 Page ID #:8536
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 2 of 55 Page ID
`#:8423
`
`04/22/22
`
`Plaintiff,
`
`
`
`v.
`
`UNITED STATES DISTRICT COURT
`CENTRAL DISTRICT OF CALIFORNIA
`
`FEDERAL TRADE COMMISSION,
`Case No. 8:20-cv-01431-PSG-KES
`
`JS-6
`
`
`
`
`[PROPOSED] FINAL ORDER FOR
`
`PERMANENT INJUNCTION AND
`
`MONETARY JUDGMENT
`QYK BRANDS LLC d/b/a Glowyy, et
`al.
`
`
`
`
`
`
`
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`Defendants.
`
`On August 4, 2020, Plaintiff, the Federal Trade Commission (“FTC”), filed
`its Complaint for Permanent Injunction and Other Equitable Relief pursuant to
`Sections 13(b) and 19 of the Federal Trade Commission Act (“FTC Act”), 15
`U.S.C. §§ 53(b) and 57b, and the FTC’s Trade Regulation Rule Concerning the
`Sale of Mail, Internet, or Telephone Order Merchandise (“MITOR” or the “Rule”),
`16 C.F.R. Part 435. Plaintiff filed its First Amended Complaint on May 19, 2021
`(ECF No. 73, “FAC”). On February 14, 2022, Plaintiff filed its Motion for
`Summary Judgment (“Motion”), as well as its Statement of Undisputed Facts, as
`supported by declarations, stipulation, admissions, interrogatory answers, or other
`materials submitted in support of the Motion. Having considered the Motion and
`supporting materials in the record and any oppositions thereto, the Court finds
`there is no genuine dispute of material fact, and the FTC is entitled to judgment
`against all Defendants as a matter of law. The Court’s reasoning and specific
`findings are detailed in the Minute Order dated April 6, 2022 (ECF No. 212).
`
`1
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 2 of 26 Page ID #:8537
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 3 of 55 Page ID
`#:8424
`
`
`
`THEREFORE, IT IS ORDERED as follows:
`FINDINGS
`A.
`This Court has jurisdiction over the subject matter of this case, and
`there is good cause to believe that it will have jurisdiction over all parties hereto
`and that venue in this district is proper.
`B.
`The Complaint alleges that Defendants participated in deceptive and
`unfair acts or practices in violation of Sections 5 and 12 of the FTC Act, 15 U.S.C.
`§ 45 and § 52, and of the Commission’s Trade Regulation Rule Concerning the
`Sale of Mail, Internet or Telephone Order Merchandise, 16 C.F.R. Part 435
`(“MITOR”), by representing they would ship goods, including Personal Protective
`Equipment (“PPE”) and hand sanitizer, within certain timeframes but having no
`reasonable basis to expect to ship the goods within the advertised timeframes;
`failing to ship goods within the timeframe required by MITOR; failing to offer
`consumers the opportunity to consent to a delay in shipping or to cancel their order
`and receive a prompt refund upon becoming aware of their inability to ship goods
`within the time advertised; and, after receiving cancellation and refund requests,
`failing to provide consumers with a prompt refund. The Complaint also charges
`that Defendants participated in deceptive acts or practices in violation of Section 5
`of the FTC Act, 15 U.S.C. § 45, by misrepresenting that they: (1) would ship
`orders “Today”; or would ship within 7 days; (2) had certain PPE and hand
`sanitizer in stock and ready to ship; and (3) would ship the goods consumers
`ordered; and that they further violated Sections 5 and 12 of the FTC Act by
`participating in deceptive acts and practices by misrepresenting that their product,
`Basic Immune IGG, could treat, prevent, or reduce risk of contracting COVID-19,
`and that it was clinically shown and approved by the FDA to do so.
`C. Defendants’ activities are in or affecting commerce, as defined in
`Section 4 of the FTC Act, 15 U.S.C. § 44.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`2
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 3 of 26 Page ID #:8538
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 4 of 55 Page ID
`#:8425
`
`
`
`D. Corporate Defendants violated Section 5 of the FTC Act, 15 U.S.C. §
`45, and MITOR, 16 C.F.R. Part 435, by representing they would ship goods,
`including hand sanitizer and PPE, within certain timeframes but having no
`reasonable basis to expect to ship the goods within the advertised timeframes;
`failing to ship goods within the timeframe required by MITOR; failing to offer
`consumers the opportunity to consent to a delay in shipping or to cancel their order
`and receive a prompt refund upon becoming aware of their inability to ship goods
`within the time advertised; and, after receiving cancellation and refund requests,
`failing to provide consumers with a prompt refund. Corporate Defendants further
`violated Section 5 of the FTC Act, 15 U.S.C. § 45, by misrepresenting that they:
`(1) would ship orders “Today”; or would ship within 7 days; (2) had certain PPE
`and hand sanitizer in stock and ready to ship; and (3) would ship the goods
`consumers ordered; and that they further violated Sections 5 and 12 of the FTC Act
`by participating in deceptive acts and practices by misrepresenting that their
`product, Basic Immune IGG, could treat, prevent, or reduce risk of contracting
`COVID-19, and that it was clinically shown and approved by the FDA to do so.
`E.
`Individual Defendants Rakesh Tammabattula and Jacqueline Thao
`Nguyen participated in and had authority to control the Corporate Defendants’
`deceptive marketing and sale of hand sanitizer, PPE products, and Basic Immune
`IGG.
`
`F.
`In light of Defendants’ conduct, there is a cognizable danger that they
`will continue to engage in activities that violate the FTC Act unless enjoined from
`such acts and practices.
`
`DEFINITIONS
`For the purpose of this Order, the following definitions apply:
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`3
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 4 of 26 Page ID #:8539
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 5 of 55 Page ID
`#:8426
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`“Applicable Time Period” means the time stated in Defendants’
`A.
`solicitation or within 30 days of Receipt of a Properly Completed Order if no time
`is stated in the solicitation.
`“Clearly and Conspicuously” means that a required disclosure is
`B.
`difficult to miss (i.e., easily noticeable) and easily understandable by ordinary
`consumers, including in all of the following ways:
`1.
`In any communication that is solely visual or solely audible, the
`disclosure must be made through the same means through which the
`communication is presented. In any communication made through both
`visual and audible means, such as a television advertisement, the disclosure
`must be presented simultaneously in both the visual and audible portions of
`the communication even if the representation requiring the disclosure is
`made in only one means.
`2.
`A visual disclosure, by its size, contrast, location, the length of
`time it appears, and other characteristics, must stand out from any
`accompanying text or other visual elements so that it is easily noticed, read,
`and understood.
`3.
`An audible disclosure, including by telephone or streaming
`video, must be delivered in a volume, speed, and cadence sufficient for
`ordinary consumers to easily hear and understand it.
`4.
`In any communication using an interactive electronic medium,
`such as the Internet or software, the disclosure must be unavoidable.
`5.
`The disclosure must use diction and syntax understandable to
`ordinary consumers and must appear in each language in which the
`representation that requires the disclosure appears.
`6.
`The disclosure must comply with these requirements in each
`medium through which it is received, including all electronic devices and
`face-to-face communications.
`
`
`
`4
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 5 of 26 Page ID #:8540
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 6 of 55 Page ID
`#:8427
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`7.
`The disclosure must not be contradicted or mitigated by, or
`inconsistent with, anything else in the communication.
`8. When the representation or sales practice targets a specific
`audience, such as children, the elderly, or the terminally ill, “ordinary
`consumers” includes reasonable members of that group.
`“Corporate Defendant(s)” means QYK Brands LLC d/b/a Glowyy,
`C.
`DrJsNatural LLC, Theo Pharmaceuticals, Inc., and EASII, Inc., and each of their
`subsidiaries, affiliates, successors, and assigns.
`“Covered Dietary Supplement” means any Dietary Supplement,
`D.
`Food, or Drug, including Basic Immune IGG.
`“Defendants” means all of the Individual Defendants and the
`E.
`Corporate Defendants, individually, collectively, or in any combination.
`“Dietary Supplement” means: (1) any product labeled as a dietary
`F.
`supplement or otherwise represented as a dietary supplement; or (2) any pill, tablet,
`capsule, powder, softgel, gelcap, liquid, or other similar form containing one or
`more ingredients that are a vitamin, mineral, herb or other botanical, amino acid,
`probiotic, or other dietary substance for use by humans to supplement the diet by
`increasing the total dietary intake, or a concentrate, metabolite, constituent, extract,
`or combination of any ingredient described above, that is intended to be ingested,
`and is not represented to be used as a conventional food or as a sole item of a meal
`or the diet.
`“Document” is synonymous in meaning and equal in scope to the
`G.
`usage of “document” and “electronically stored information” in Federal Rule of
`Civil Procedure 34(a), Fed. R. Civ. P. 34(a), and includes writings, drawings,
`graphs, charts, photographs, sound and video recordings, images, Internet sites,
`web pages, websites, electronic correspondence, including e-mail and instant
`messages, contracts, accounting data, advertisements, FTP Logs, Server Access
`Logs, books, written or printed records, handwritten notes, telephone logs,
`
`
`
`5
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 6 of 26 Page ID #:8541
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 7 of 55 Page ID
`#:8428
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`telephone scripts, receipt books, ledgers, personal and business canceled checks
`and check registers, bank statements, appointment books, computer records,
`customer or sales databases and any other electronically stored information,
`including Documents located on remote servers or cloud computing systems, and
`other data or data compilations from which information can be obtained directly or,
`if necessary, after translation into a reasonably usable form. A draft or non-
`identical copy is a separate Document within the meaning of the term.
`“Drug” means: (1) articles recognized in the official United States
`H.
`Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or
`official National Formulary, or any supplement to any of them; (2) articles
`intended for use in the diagnosis, cure, mitigation, treatment, or prevention of
`disease in humans or other animals; (3) articles (other than food) intended to affect
`the structure or any function of the body of humans or other animals; and (4)
`articles intended for use as a component of any article specified in (1), (2), or (3);
`but does not include devices or their components, parts, or accessories.
`“Essentially Equivalent Product” means a product that contains the
`I.
`identical ingredients, except for inactive ingredients (e.g., binders, colors, fillers,
`excipients) in the same form and dosage, and with the same route of administration
`(e.g., orally, sublingually), as the Covered Dietary Supplement; provided that the
`Covered Dietary Supplement may contain additional ingredients if reliable
`scientific evidence generally accepted by experts in the field indicates that the
`amount and combination of additional ingredients is unlikely to impede or inhibit
`the effectiveness of the ingredients in the Essentially Equivalent Product.
`“Food” means: (1) any article used for food or drink for humans or
`J.
`other animals; (2) chewing gum; and (3) any article used for components of any
`such article.
`“Individual Defendants” means Rakesh Tammabattula and
`K.
`Jacqueline Thao Nguyen.
`
`
`
`6
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 7 of 26 Page ID #:8542
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 8 of 55 Page ID
`#:8429
`
`
`
`“Option” means an offer made Clearly and Conspicuously and
`L.
`without prior demand.
`“Personal Protective Equipment” means protective clothing,
`M.
`helmets, gloves, face shields, goggles, facemasks, respirators, or other equipment
`designed, intended or represented to protect the wearer from the spread of infection
`or illness.
`“Prompt,” in the context of a Refund, means a Refund sent by any
`N.
`means at least as fast and reliable as first-class mail within 7 days of the date on
`which the buyer’s right to Refund vests under the provisions of this Court Order.
`Provided, however, that where a Defendant cannot provide a Refund by the same
`method payment was tendered, Prompt Refund means a Refund sent in the form of
`cash, check, or money order, by any means at least as fast and reliable as first class
`mail, within 7 days of the date on which the Defendant discovers it cannot provide
`a Refund by the same method as payment was tendered.
`“Protective Goods and Services” means any good or service
`O.
`designed, intended, or represented to detect, treat, prevent, mitigate, or cure
`COVID-19 or any other infection or disease, including, but not limited to, Personal
`Protective Equipment, hand sanitizer, and thermometers.
`“Refund” means:
`P.
`1. Where the buyer tendered full payment for the unshipped
`merchandise in the form of cash, check, or money order,
`a return of the amount tendered in the form of cash,
`check, or money order sent to the buyer;
`2. Where there is a credit sale:
`(i) And Defendant is a creditor, a copy of a credit
`memorandum or the like or an account statement
`sent to the buyer reflecting the removal or absence
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`7
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 8 of 26 Page ID #:8543
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 9 of 55 Page ID
`#:8430
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`of any remaining charge incurred as a result of the
`sale from the buyer’s account;
`(ii) And a third party is the creditor, an appropriate
`credit memorandum or the like sent to the third
`party creditor which will remove the charge from
`the buyer’s account and a copy of the credit
`memorandum or the like sent to the buyer that
`includes the date that Defendant sent the credit
`memorandum or the like to the third party creditor
`and the amount of the charge to be removed, or a
`statement from Defendant acknowledging the
`cancellation of the order and representing that it
`has not taken any action regarding the order which
`will result in a charge to the buyer’s account with
`the third party;
`(iii) And the buyer tendered partial payment for the
`unshipped merchandise in the form of cash, check,
`or money order, a return of the amount tendered in
`the form of cash, check, or money order sent to the
`buyer.
`3. Where the buyer tendered payment for the unshipped
`merchandise by any means other than those enumerated
`in (1) or (2) of this definition:
`(i)
`Instructions sent to the entity that transferred
`payment to Defendant instructing that entity to
`return to the buyer the amount tendered in the form
`tendered and a statement sent to the buyer setting
`forth the instructions sent to the entity including
`
`
`
`8
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 9 of 26 Page ID #:8544
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 10 of 55 Page ID
`#:8431
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`the date of the instructions and the amount to be
`returned to the buyer;
`(ii) A return of the amount tendered in the form of
`cash, check or money order sent to the buyer; or
`(iii) A statement from Defendant sent to the buyer
`acknowledging the cancellation of the order and
`representing that Defendant has not taken any
`action regarding the order which will access any of
`the buyer’s funds.
`“Receipt of a Properly Completed Order” means, where the buyer
`Q.
`tenders full or partial payment in the proper amount in the form of cash, check or
`money order; authorization from the buyer to charge an existing charge account; or
`other payment methods, the time at which Defendant receives both said payment
`and an order from the buyer containing all of the information needed by Defendant
`to process and Ship the order.
`“Ship,” or any variation thereof, including Shipment or Shipping,
`R.
`means the act by which the merchandise is physically placed in the possession of
`the carrier.
`
`ORDER
`CONDUCT RELIEF
`I.
`IT IS ORDERED that Defendants are permanently restrained and enjoined
`from the advertising, marketing, promoting, or offering for sale, or assisting others
`in the advertising, marketing, promoting, or offering for sale, of any Protective
`Goods and Services.
`
`II.
`
`9
`
`
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 10 of 26 Page ID
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 11 of 55 Page ID
`#:8545
`#:8432
`
`
`
`IT IS FURTHER ORDERED that Defendants, Defendants’ officers,
`agents, employees, and attorneys, and all other persons in active concert or
`participation with any of them, who receive actual notice of this Order, whether
`acting directly or indirectly, in connection with the sale of any good ordered by
`mail, via the internet, or by telephone are permanently restrained and enjoined
`from:
`
`A. Representing, without a reasonable basis, that Defendants will:
`(1) Ship ordered goods within the time stated in their solicitation; or (2) Ship
`ordered goods by any revised Shipping date provided to buyers.
`B. Where the order solicitation does not Clearly and Conspicuously state
`a Shipping time, soliciting any order for the sale of merchandise without having a
`reasonable basis that the goods will Ship 30 days after Receipt of a Properly
`Completed Order.
`C.
`Informing buyers that Defendants are unable to make any
`representation regarding the length of any Shipping delay unless Defendants have a
`reasonable basis for so informing buyers.
`D.
`Failing to provide buyers with the Option either to consent to the
`delay in Shipping or to cancel the order and receive a Prompt Refund where
`Defendants cannot Ship the ordered goods within the Applicable Time Period.
`Said Option must be provided within a reasonable time after the Defendants have
`become aware of their inability to Ship within the Applicable Time Period, but in
`no event later than the Applicable Time Period.
`1.
`Provided however, that any such Option must either:
`a.
`provide a definite revised Shipping date; or
`b. where Defendants lack a reasonable basis for providing a
`definite revised Shipping date, inform the buyer that:
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`10
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 11 of 26 Page ID
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 12 of 55 Page ID
`#:8546
`#:8433
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`i. the seller is unable to make any representation
`regarding the length of the delay; and
`ii. the reason(s) for the delay.
`2. Where Defendants have provided a definite revised Shipping
`date, pursuant to II.D.1.a, that is more than 30 days later than the
`Applicable Time Period, Defendants must also Clearly and
`Conspicuously inform the buyer that the buyer’s order will
`automatically be deemed to have been cancelled unless:
`a. Defendants have Shipped the merchandise within the
`Applicable Time Period, and Defendants have received no
`cancellation request prior to Shipment; or
`b.
`the buyer has specifically consented to said Shipping
`delay within the Applicable Time Period.
`3. Where Defendants have informed the buyer that they cannot
`make any representation regarding the length of the delay pursuant to
`Section II.D.1.b, Defendants must also Clearly and Conspicuously
`inform the buyer that the buyer’s order will automatically be deemed
`to have been cancelled unless:
`a. Defendants have Shipped the merchandise within 30 days
`of the Applicable Time Period, and the Defendants have
`received no cancellation request prior to Shipment; or
`b.
`the buyer has specifically consented to said Shipping
`delay within 30 days of the Applicable Time Period. Provided
`however, Defendants must also expressly inform the buyer that
`the buyer will have a continuing right to cancel the order at any
`time after the Applicable Time Period.
`E. Where the buyer has consented to a definite revised Shipping date
`pursuant to Section II.D, and Defendants become aware they are unable to Ship
`
`
`
`11
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 12 of 26 Page ID
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 13 of 55 Page ID
`#:8547
`#:8434
`
`
`
`ordered goods by that date, failing to provide a renewed Option either to consent to
`a further delay or to cancel the order and receive a Prompt Refund. Said Option
`must be made within a reasonable time after the Defendants first become aware of
`their inability to Ship before the said definite revised Shipping date, but in no event
`later than the expiration of the definite revised Shipping date. Provided however,
`that any such Option must provide a new definite revised Shipping date, unless
`Defendants lack a reasonable basis for doing so. In such event, Defendants must
`also provide the notices required by Section II.D.1.b and Section II.D.3 of this
`Order.
`F.
`Refund:
`
`Failing to cancel any order and provide the buyer with a Prompt
`
`1. When Defendants have received a cancellation and Refund
`request from the buyer pursuant to Section II of this Order;
`
`2.
`Under the circumstances prescribed in Section II.D.2 and
`II.D.3;
`
`3. When Defendants fail to provide the Option required by Section
`II.D. and have not shipped the merchandise within the Applicable
`Time Period; or
`
`4. When Defendants notify the buyer that they have decided not to
`Ship the merchandise.
`
`III.
`In any action brought by the Commission alleging a violation of Section II
`of this Order, the failure to create and maintain records establishing compliance
`with Section II creates a rebuttable presumption that Defendants violated the
`provisions of that Section.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`12
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 13 of 26 Page ID
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 14 of 55 Page ID
`#:8548
`#:8435
`
`
`
`IV.
`IT IS FURTHER ORDERED that Defendants, Defendants’ officers,
`agents, employees, and attorneys, and all other persons in active concert or
`participation with any of them, who receive actual notice of this Order, whether
`acting directly or indirectly, in connection with the sale of any good or service
`ordered by mail, via the internet, or by telephone are permanently restrained and
`enjoined from, or assisting others in, expressly or by implication, misrepresenting:
`
`A.
`
`B.
`
`The time within which the good will ship;
`
`The time within which the buyer will receive the ordered good;
`
`C.
`That any costs will be refunded if the order does not arrive on time, or
`any material aspect of a Refund policy; or
`
`D. Any other fact material to consumers concerning any good or service,
`such as: the total costs; any material restrictions, limitations, or conditions; or any
`material aspect of its performance, efficacy, nature, or central characteristics.
`V.
`IT IS FURTHER ORDERED that Defendants, Defendants’ officers,
`agents, employees, and attorneys, and all other persons in active concert or
`participation with any of them, who receive actual notice of this Order, whether
`acting directly or indirectly, in connection with the labeling, advertising,
`promotion, offering for sale, sale, or distribution of any Covered Dietary
`Supplement, are permanently restrained and enjoined from making, or assisting
`others in making, expressly or by implication, including through the use of a
`product or program name, endorsement, depiction, or illustration, any
`representation that such product:
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`13
`
`

`

`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 14 of 26 Page ID
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 15 of 55 Page ID
`#:8549
`#:8436
`
`
`
`A.
`is FDA-approved to effectively treat, prevent transmission of, or
`reduce the risk of contracting COVID-19 unless the representation is true and non-
`misleading;
`B.
`can effectively treat, prevent transmission of, or reduce risk of
`contracting COVID-19; or
`C.
`cures, mitigates, or treats any disease, unless the representation in B or
`C is true and non-misleading, and, at the time such representation is made,
`Defendants possess and rely upon competent and reliable scientific evidence that is
`sufficient in quality and quantity based on standards generally accepted in the
`relevant scientific fields, when considered in light of the entire body of relevant
`and reliable scientific evidence, to substantiate that the representation is true.
`For purposes of this Section, competent and reliable scientific evidence must
`consist of human clinical testing of the Covered Dietary Supplement, or of an
`Essentially Equivalent Product, that is sufficient in quality and quantity based on
`standards generally accepted by experts in the relevant disease, condition, or
`function to which the representation relates, when considered in light of the entire
`body of relevant and reliable scientific evidence, to substantiate that the
`representation is true. Such testing must be: (1) randomized, double-blind, and
`placebo-controlled; and (2) conducted by researchers qualified by training and
`experience to conduct such testing. In addition, all underlying or supporting data
`and Documents generally accepted by experts in the field as relevant to an
`assessment of such testing as described in the Section entitled Preservation of
`Records Relating to Competent and Reliable Human Clinical Tests or Studies must
`be available for inspection and production to the Commission. Persons covered by
`this Section have the burden of proving that a product satisfies the definition of
`Essentially Equivalent Product.
`
`VI.
`
`14
`
`
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 15 of 26 Page ID
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 16 of 55 Page ID
`#:8550
`#:8437
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`IT IS FURTHER ORDERED that Defendants, Defendants’ officers,
`agents, employees, and attorneys, and all other persons in active concert or
`participation with any of them, who receive actual notice of this Order, whether
`acting directly or indirectly, in connection with the manufacturing, labeling,
`advertising, promotion, offering for sale, sale, or distribution of any Covered
`Dietary Supplement, are permanently restrained and enjoined from making, or
`assisting others in making, expressly or by implication, including through the use
`of a product or program name, endorsement, depiction, or illustration, any
`representation, other than representations covered under the Section IV of this
`Order, about the health benefits, performance, efficacy, safety, or side effects of
`any Covered Dietary Supplement, unless the representation is non-misleading, and,
`at the time of making such representation, they possess and rely upon competent
`and reliable scientific evidence that is sufficient in quality and quantity based on
`standards generally accepted by experts in the relevant disease, condition, or
`function to which the representation relates, when considered in light of the entire
`body of relevant and reliable scientific evidence, to substantiate that the
`representation is true.
`For purposes of this Section, competent and reliable scientific evidence
`means tests, analyses, research, or studies (1) that have been conducted and
`evaluated in an objective manner by experts in the relevant disease, condition, or
`function to which the representation relates; (2) that are generally accepted by such
`experts to yield accurate and reliable results; and (3) that are randomized, double-
`blind, and placebo-controlled human clinical testing of the Covered Product, or of
`an Essentially Equivalent Product, when such experts would generally require such
`human clinical testing to substantiate that the representation is true. In addition,
`when such tests or studies are human clinical tests or studies, all underlying or
`supporting data and documents generally accepted by experts in the field as
`relevant to an assessment of such testing as set forth in the Section entitled
`
`
`
`15
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 16 of 26 Page ID
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 17 of 55 Page ID
`#:8551
`#:8438
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`Preservation of Records Relating to Competent and Reliable Human Clinical Tests
`or Studies must be available for inspection and production to the Commission.
`Persons covered by this Section have the burden of proving that a product satisfies
`the definition of Essentially Equivalent Product.
`
`
`
`VII.
`IT IS FURTHER ORDERED that Defendants, Defendants’ officers,
`agents, employees, and attorneys, and all other persons in active concert or
`participation with any of them, who receive actual notice of this Order, whether
`acting directly or indirectly, in connection with the manufacturing, labeling,
`advertising, promotion, offering for sale, sale, or distribution of any Covered
`Dietary Supplement are permanently restrained and enjoined from misrepresenting,
`in any manner, expressly or by implication, including through the use of any
`product name, endorsement, depiction, or illustration:
`A.
`That any Covered Dietary Supplement is clinically proven to treat,
`prevent the transmission of, or reduce the risk of contracting COVID-19;
`B.
`That the performance or benefits of any product are scientifically or
`clinically proven or otherwise established; or
`C.
`The existence, contents, validity, results, conclusion, or interpretations
`of any test, study, or other research.
`
`VIII.
`IT IS FURTHER ORDERED that nothing in this Order prohibits
`Defendants, Defendants’ officers, agents, employees, and attorneys, or all other
`persons in active concert or participation with any of them from:
`A.
`For any Drug product, making a representation that is approved for
`inclusion in labeling for such Drug product under a new drug application or
`biologics license application approved by the Food and Drug Administration, or,
`
`
`
`16
`
`

`

`Case 8:20-cv-01431-PSG-KES Document 214 Filed 04/22/22 Page 17 of 26 Page ID
`Case 8:20-cv-01431-PSG-KES Document 213-1 Filed 04/20/22 Page 18 of 55 Page ID
`#:8552
`#:8439
`
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`2

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket